EGFR and non-small cell lung carcinoma: For example, FGF-2-FGFR-1 activation through an autocrine loop was found as a mechanism of acquired resistance in non-small cell lung cancer (NSLC) to EGFR-tyrosine kinase inhibitor gefitinib [30,31].